FDA's Risk Evaluation Guidance Brings Clarity, Not Solutions

By Paul Dietze and Elizabeth Crompton (April 26, 2019, 4:40 PM EDT) -- This April, the U.S. Food and Drug Administration issued final guidance clarifying how the FDA applies the factors in section 505-1 of the Federal Food, Drug and Cosmetic Act[1] to determine whether a risk evaluation and mitigation strategy is necessary to ensure that the benefits of a drug outweigh its risks....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Read the full article

Already a subscriber? Click here to login